EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials

Domenica Rubino iD, Jakob B Bjorner iD, Naveen Rathor, Arya M Sharma iD, Lisa von Huth Smith, Sean Wharton iD, Thomas Wadden iD, Niels Zeuthen, Ronette L Kolotkin iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15620 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Domenica Rubino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Washington Center for Weight Management and Research, Arlington, Virginia, USA. Hauptthemen laut MEDLINE: Quality of Life, Glucagon-Like Peptides, Patient Reported Outcome Measures, Obesity. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To summarize the effects of semaglutide 2.4 mg on weight‐related quality of life (WRQOL) and health‐related quality of life (HRQOL), focusing on the confirmatory secondary endpoint of physical functioning. Materials and Methods The STEP 1–4 Phase 3a, 68‐week, double‐blind, randomized controlled trials assessed the efficacy and safety of semaglutide 2.4 mg versus placebo in individuals with overweight/obesity. WRQOL and HRQOL were assessed by change from baseline to Week 68 in two different but complementary measures, the Impact of Weight on Quality of Life‐Lite Clinical Trials Version (IWQOL‐Lite‐CT; STEP 1 and 2) and the SF‐36v2 Health Survey Acute (SF‐36v2; STEP 1–4).

Results

Superiority for semaglutide 2.4 mg over placebo based on IWQOL‐Lite‐CT and SF‐36v2 physical functioning scores was confirmed in STEP 1 and 2 and in STEP 1, 2 and 4, respectively. At Week 68, a greater proportion of participants treated with semaglutide 2.4 mg than with placebo reached meaningful within‐person change (MWPC) thresholds for IWQOL‐Lite‐CT Physical Function scores in STEP 1 (51.8% vs. 28.3%; p < 0.0001) and STEP 2 (39.6% vs. 29.5%; p = 0.0083) and the MWPC threshold for SF‐36v2 Physical Functioning in STEP 1 (39.8% vs. 24.1%; p < 0.0001), STEP 2 (41.0% vs. 27.3%; p = 0.0005) and STEP 4 (18.0% vs. 6.6%; p < 0.0001). All other IWQOL‐Lite‐CT and SF‐36v2 scale scores in STEP 1–4 were numerically improved with semaglutide 2.4 mg versus placebo, except for SF‐36v2 Role Emotional in STEP 2.

Conclusions

Semaglutide 2.4 mg significantly improved physical functioning, with greater proportions of participants achieving MWPC compared with placebo, and showed beneficial effects on WRQOL and HRQOL beyond physical functioning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeGlucagon-Like PeptidesPatient Reported Outcome MeasuresObesityOverweightHumansMaleFemaleMiddle AgedDouble-Blind MethodAdultWeight LossHypoglycemic AgentsSemaglutide

Stichwörter der Autor:innen

GLP‐1obesity therapypatient‐reported outcomessemaglutideweight control

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Washington Center for Weight Management and Research, Arlington, Virginia, USA.
  • QualityMetric Inc., LLC, Johnston, Rhode Island, USA.
  • Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • York University, McMaster University and Wharton Weight Management Clinic, Toronto, Ontario, Canada.

ORCID-Profile: Domenica Rubino, Jakob B Bjorner, Arya M Sharma, Sean Wharton, Thomas Wadden, Ronette L Kolotkin

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Rubino, D., Bjorner, J. B., Rathor, N., Sharma, A. M., von Huth Smith, L., Wharton, S., Wadden, T., Zeuthen, N., & Kolotkin, R. L. (2024). Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15620

Vancouver

Rubino D, Bjorner JB, Rathor N, Sharma AM, von Huth Smith L, Wharton S, et al. Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15620

BibTeX
@article{Rubino2024,
  author = {Rubino, Domenica and Bjorner, Jakob B and Rathor, Naveen and Sharma, Arya M and von Huth Smith, Lisa and Wharton, Sean and Wadden, Thomas and Zeuthen, Niels and Kolotkin, Ronette L},
  title = {Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15620}
}
Kostenlos starten →